ICU Medical, Inc. (NASDAQ:ICUI) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC increased its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 27.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 716 shares of the medical instruments supplier’s stock after acquiring an additional 153 shares during the quarter. GAMMA Investing LLC’s holdings in ICU Medical were worth $99,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of ICUI. Harvest Fund Management Co. Ltd acquired a new stake in ICU Medical during the fourth quarter worth approximately $33,000. Quarry LP boosted its holdings in shares of ICU Medical by 764.3% in the 4th quarter. Quarry LP now owns 242 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 214 shares during the last quarter. Murphy & Mullick Capital Management Corp acquired a new position in shares of ICU Medical in the 4th quarter valued at $52,000. Russell Investments Group Ltd. boosted its holdings in shares of ICU Medical by 88.8% in the 4th quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 300 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its holdings in shares of ICU Medical by 813.5% in the 4th quarter. Sterling Capital Management LLC now owns 676 shares of the medical instruments supplier’s stock valued at $105,000 after purchasing an additional 602 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Activity at ICU Medical

In other ICU Medical news, insider Ben Sousa sold 2,000 shares of the firm’s stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $137.36, for a total transaction of $274,720.00. Following the completion of the transaction, the insider directly owned 479 shares of the company’s stock, valued at $65,795.44. This trade represents a 80.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Christian B. Voigtlander sold 5,556 shares of the firm’s stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $138.65, for a total transaction of $770,339.40. Following the transaction, the chief operating officer directly owned 2,389 shares of the company’s stock, valued at approximately $331,234.85. This represents a 69.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,097 shares of company stock valued at $4,860,156 in the last 90 days. 1.50% of the stock is currently owned by insiders.

ICU Medical Stock Performance

Shares of ICUI stock opened at $135.50 on Monday. ICU Medical, Inc. has a 52 week low of $117.92 and a 52 week high of $196.26. The company has a market cap of $3.33 billion, a PE ratio of -35.38 and a beta of 0.87. The company has a current ratio of 2.59, a quick ratio of 1.52 and a debt-to-equity ratio of 0.75. The company’s fifty day simple moving average is $134.12 and its 200-day simple moving average is $145.63.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.49. ICU Medical had a negative net margin of 3.87% and a positive return on equity of 6.75%. The firm had revenue of $599.49 million for the quarter, compared to the consensus estimate of $574.15 million. During the same quarter in the previous year, the firm posted $0.96 EPS. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. As a group, equities research analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current year.

Analyst Upgrades and Downgrades

ICUI has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Sunday, May 18th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Tuesday, April 8th. KeyCorp cut their target price on shares of ICU Medical from $209.00 to $191.00 and set an “overweight” rating on the stock in a research note on Monday, April 21st. Finally, Raymond James Financial cut their target price on shares of ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating on the stock in a research note on Friday, May 9th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $192.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.